Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5867 Articles

Douglas A. McIntyre | Feb 13, 2007 at 4:07 AM EST

Amphastar and Teva Prevail Over Aventis, May Still Not Receive FDA Approval

by Robert S. Dailey Aventis Pharma v. Amphastar Pharms., No. 03-cv-887 (C.D. Cal. 2007) In a ruling issued last Friday,…

Douglas A. McIntyre | Feb 12, 2007 at 9:17 AM EST

Onyx Pharma Soars on Liver Cancer Drug

Onyx Pharmaceuticals (ONXX-NASDAQ) is probably as happy as you could imagine that it partnered with Bayer (BAY-NYSE/ADR). ONXX shares are…

Douglas A. McIntyre | Feb 12, 2007 at 4:13 AM EST

Raggedy Ann and the Anti-Vaccination Movement

by H.S. AyoubBioHealth Investor.com It was in 1796 that Edward Jenner successfully immunized a child against smallpox, and his experiment…

Douglas A. McIntyre | Feb 12, 2007 at 4:11 AM EST

Q3 is Key for Thermogenesis

Thermogenesis Corp (KOOL), a developer of cord blood collection and processing units, released subpar fiscal second quarter results on Friday.…

Douglas A. McIntyre | Feb 12, 2007 at 4:10 AM EST

Gilead Q4 Report: Preview of Great Things to Come

by JMHOBioTechnology Stock Blog Gilead (GILD) is a large biotech company with a portfolio of marketed products that include royalties…

Douglas A. McIntyre | Feb 10, 2007 at 12:08 PM EST

Friday’s Top Biotech and Medical Stocks

From BioHealth Investor Biotechnology REXAHN PHARMACEUTICL [RXHN.OB] +18.18% LPATH INC [LPTN.OB] +14.29% NEURALSTEM INC [NRLS.OB] +8.60% CELL GENESYS INC [CEGE]…

Douglas A. McIntyre | Feb 9, 2007 at 4:22 AM EST

Thursday’s Top Biotech and Medical Stocks

From BioHealth Investor Biotechnology AURIGA LABORATORIES [ARGA.OB] +22.32% ACCENTIA BIOPHARMACE [ABPI] +12.09% XENOPORT [XNPT] +11.09% CADENCE PHARM. INC. [CADX] +10.07%…

Douglas A. McIntyre | Feb 8, 2007 at 3:28 AM EST

Wednesday’s Top Biotech and Medical Stocks

From BioHealth Investor Biotechnology DYAX CORP [DYAX] +9.51% FERMAVIR PHARMACEUTL [FMVR.OB] +8.57% ZIOPHARM ONCOLOGY IN [ZIOP] +7.30% ALNYLAM PHARMACEUT [ALNY]…

Douglas A. McIntyre | Feb 8, 2007 at 3:27 AM EST

Federal Funding Constraints Forces Elimination of Cancer Trials

by H.S. AyoubBioHealth Investor.com Due to federal budget constraints some 3000 patients could possibly be prevented from taking part in…

Douglas A. McIntyre | Feb 8, 2007 at 3:26 AM EST

Follow Along with Dr. Frost and Invest in Continucare

One strategy that I like to follow when looking at smaller capped stocks is to keep an eye on company…

Douglas A. McIntyre | Feb 7, 2007 at 6:52 PM EST

Cramer Interviewed Celgene’s CEO

Cramer interviewed the CEO (Robert Hugin) of Celgene (CELG-NASDAQ), one name he has been very positive on before. Cramer said…

Douglas A. McIntyre | Feb 7, 2007 at 11:16 AM EST

3SBio IPO: Chinese Biotech Success

3SBio Inc. (SSRX-NASDAQ) opened at a premium to its pricing out of the chute today. The company priced 7.7 million…

Douglas A. McIntyre | Feb 7, 2007 at 4:04 AM EST

Tuesday’s Top Biotech and Medical Stocks

From BioHealth Investor Biotechnology XOMA LTD [XOMA] +11.15% DYADIC INTERNATIONAL [DIL] +9.27% ADVENTRX PHARMACTL [ANX] +6.01% VION PHARM INC [VION]…

Douglas A. McIntyre | Feb 7, 2007 at 4:03 AM EST

Thermogenesis Responds to FDA Questions

by H.S. AyoubBioHealth Investor.com On Tuesday Thermogenesis Corp (KOOL) announced that it had submitted the necessary paperwork answering certain questions…

Douglas A. McIntyre | Feb 6, 2007 at 4:00 AM EST

Monday’s Top Biotech and Medical Stocks

From BioHealth Investor Biotechnology HEMOBIOTECH INC [HMBT.OB] +9.52% AFFYMAX, INC. [AFFY] +7.03% OSIRIS THERAPEUTICS [OSIR] +6.93% IDM PHARMA INC [IDMI]…

1 … 381 382 383 384 385 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Amphastar and Teva Prevail Over Aventis, May Still Not Receive FDA Approval

Onyx Pharma Soars on Liver Cancer Drug

Raggedy Ann and the Anti-Vaccination Movement

Q3 is Key for Thermogenesis

Gilead Q4 Report: Preview of Great Things to Come

Friday’s Top Biotech and Medical Stocks

Thursday’s Top Biotech and Medical Stocks

Wednesday’s Top Biotech and Medical Stocks

Federal Funding Constraints Forces Elimination of Cancer Trials

Follow Along with Dr. Frost and Invest in Continucare

Cramer Interviewed Celgene’s CEO

3SBio IPO: Chinese Biotech Success

Tuesday’s Top Biotech and Medical Stocks

Thermogenesis Responds to FDA Questions

Monday’s Top Biotech and Medical Stocks

NVDL’s 2x Promise Delivered Only 17.21% While NVIDIA Soared 22.21% in One Year

Your 5% CD Is Gone and the Bank’s Renewal Offer Is Insulting. These 3 ETFs Keep Paying After the Fed Stops

ISPY’s 0.56% Fee Hides a $38,000 Decade-Long Performance Gap Against SPY

How a 52-Year-Old Can Turn $425,000 Into a Monthly Paycheck Machine by 62

The Portfolio Blueprint for Building $50,000 a Month in Dividend Income

NVDL’s 2x Promise Delivered Only 17.21% While NVIDIA Soared 22.21% in One Year

Your 5% CD Is Gone and the Bank’s Renewal Offer Is Insulting. These 3 ETFs Keep Paying After the Fed Stops

Health and Healthcare Articles

All Health and Healthcare Articles

Amphastar and Teva Prevail Over Aventis, May Still Not Receive FDA Approval

Onyx Pharma Soars on Liver Cancer Drug

Raggedy Ann and the Anti-Vaccination Movement

Q3 is Key for Thermogenesis

Gilead Q4 Report: Preview of Great Things to Come

Friday’s Top Biotech and Medical Stocks

Thursday’s Top Biotech and Medical Stocks

Wednesday’s Top Biotech and Medical Stocks

Federal Funding Constraints Forces Elimination of Cancer Trials

Follow Along with Dr. Frost and Invest in Continucare

Cramer Interviewed Celgene’s CEO

3SBio IPO: Chinese Biotech Success

Tuesday’s Top Biotech and Medical Stocks

Thermogenesis Responds to FDA Questions

Monday’s Top Biotech and Medical Stocks

NVDL’s 2x Promise Delivered Only 17.21% While NVIDIA Soared 22.21% in One Year

Your 5% CD Is Gone and the Bank’s Renewal Offer Is Insulting. These 3 ETFs Keep Paying After the Fed Stops

ISPY’s 0.56% Fee Hides a $38,000 Decade-Long Performance Gap Against SPY

Featured Reads

How a 52-Year-Old Can Turn $425,000 Into a Monthly Paycheck Machine by 62

The Portfolio Blueprint for Building $50,000 a Month in Dividend Income